Ocular Therapeutix to Present Eight Posters Highlighting its Sustained Release Hydrogel Platform Technology at the Association for Research in Vision and Ophthalmology Annual Meeting
Preclinical Data on Sustained-Release Injectable Anti-VEGF Drug Depots for Back-of-the-Eye Diseases to be Presented
The data presented will focus on the company’s proprietary hydrogel
injectable depot technology using bevacizumab and other anti-VEGF agents
as model proteins to demonstrate viability of the platform as a means of
developing sustained release therapies for retinal diseases. The poster
presentations take place on
Preservation of Bevacizumab Anti-VEGF Bioactivity and Monomeric
Structure During Processing into a Sustained Release Bevacizumab
(Poster B0226) – Compatibility of protein-based drugs with the hydrogel technology.
Pharmacokinetics of Bevacizumab Sustained Release from Intravitreal
Hydrogel Depots in a Rabbit Model Compared to a single Avastin Dose
(Poster B0248) - Comparison of drug concentration in vitro and in intraocular tissues when released from the hydrogel depots containing various commercially available anti-VEGF agents compared to a conventional bolus injection of an anti-VEGF agent.
- Tolerability of Intravitreal Hydrogel Depots for Anti-VEGF Sustained Release in a Rabbit Model (Poster B0222) – Biocompatible nature of the hydrogel depot when placed in an intravitreal environment.
“We have been able to demonstrate that an anti-VEGF maintains its
structure and bioactivity within our hydrogel. We have further shown
tolerability and drug release of clinically meaningful concentration and
duration. This technology provides the possibility of a new
biocompatible, bioresorbable intravitreal hydrogel depot platform. We
look forward to advancing the development of this program,” said
Influence of Storage Temperature on Sustained Release Dexamethasone
Pharmacokinetics in a Beagle Model
(Poster C0092) Session: Physiology, pharmacology, inflammation and neuroprotection.
8:30-10:15 a.m. MDT
Dose-Based Pharmacokinetics of Sustained Release Dexamethasone in
(Poster C0093) Session: Physiology, pharmacology, inflammation and neuroprotection.
8:30-10:15 a.m. MDT
A Toxicological Evaluation of a Single Dose, 90 Day Sustained
Release Travoprost Punctum Plug in Canines (Poster D0236) Session:
Biochemistry, physiology and pharmacology of glaucoma and aqueous
11:00AM-12:45 p.m. MDT
Evaluating Sustained Release Dexamethasone for the Treatment of
Chronic Allergic Conjunctivitis Using a Modified Conjunctival Allergen
Challenge (Ora-CAC®) Model (Poster A0143)
Session: Corneal inflammation due to allergy, dry eye, or transplant.
3:45-5:30 p.m. MDT
One-Year Stability of a Sustained Release Travoprost Biodegradable
Hydrogel Punctum Plug for the Treatment of Glaucoma (Poster C0137)
Session: Drug studies and pharmacology.
8:30-10:15 a.m. MDT
Forward Looking Statements
Any statements in this press release about future expectations, plans
and prospects for the Company, including statements about the
development of the Company’s product candidates, such as the ongoing
development of the Company’s hydrogel injectable depot technology,
the advancement of the Company's other product candidates and other
statements containing the words "anticipate," "believe," "estimate,"
"expect," "intend", "goal," "may", "might," "plan," "predict,"
"project," "target," "potential," "will," "would," "could," "should,"
"continue," and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors. Such forward-looking statements involve substantial
risks and uncertainties that could cause the Company’s clinical
development programs, future results, performance or achievements to
differ significantly from those expressed or implied by the
forward-looking statements. Such risks and uncertainties include, among
others, those related to the timing and costs involved in
commercializing ReSure® Sealant, the initiation
and conduct of clinical trials, availability of data from clinical
trials and expectations for regulatory approvals, the Company’s
scientific approach and general development progress, the availability
or commercial potential of the Company’s product candidates, the
sufficiency of cash resources and need for additional financing or other
actions and other factors discussed in the “Risk Factors” section
contained in the Company’s Annual Report on Form 10-K for the year ended
Ocular Therapeutix, Inc.
Chief Financial Officer
Burns McClellan on behalf of Ocular Therapeutix
Kimberly Minarovich, 212-213-0006
Vice President of Sales and Marketing